The effect of tiotropium therapy on markers of elastin degradation in COPD

详细信息    查看全文

• 作者：Shuren Ma (1)
  Yong Y Lin (1)
  Lori Tartell (1)
  Gerard M Turino (1)
  
• 刊名：Respiratory Research
• 出版年：2009
• 出版时间：December 2009
• 年：2009
• 卷：10
• 期：1
• 全文大小：501KB
• 参考文献：1. Wright RR: Elastic tissue of normal and emphysematous lungs: a tridimensional histologic study. / Am J Path 1961, 39:355鈥?67.
  2. Chrzanowski P, Keller S, Cerreta J, Mandl I, Turino GM: Elastin content of normal and emphysematous lung parenchyma. / Amer J Med 1980, 69:351鈥?59. CrossRef
  3. Ma S, Lieberman S, Turino GM, Lin YY: The detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputum. / PNAS 2003, 100:12941鈥?2943. CrossRef
  4. Rosenbloom J: "Biochemical/immunologic markers of emphysema" Pulmonary Emphysema: the Rational for Therapeutic Intervention. In / Ann NY Acad Sci Edited by: Lohen AB. 1991, 624S:7鈥?2. CrossRef
  5. Ma S, Lin YY, Turino GM: Measurements of Desmosine and Isodesmosine by Mass Spectrometry in COPD. / CHEST 2007, 131:1363鈥?1. CrossRef
  6. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper AD Jr, Korducki L, Cassino C, Kesten S: Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator, a randomized trial. / Ann Intern Med 2005, 143:317鈥?6.
  7. Vincken W, van Noord JA, Greefhorst APM, Bantje ThA, Kesten S, Korducki L, / et al.: Improved health outcomes in patients with COPD during one year's treatment with tiotropium. / Eur Respir J 2002, 19:209鈥?6. CrossRef
  8. Casaburi R, Mahler DA, Jones PW, Wanner A, San Pedro G, ZuWallack RL, / et al.: A long-term evaluation of one-daily tiotropium in chronic obstructive pulmonary disease. / Eur Respir J 2002, 19:217鈥?4. CrossRef
  9. Celli B, ZuWallack R, Wang S, Kesten s: Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. / Chest 2003, 124:1743鈥?8. CrossRef
  10. Gosen R, Bos IS, Zaagsma J, Meurs H: Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. / AJRCCM 2005,171(10):1096鈥?102.
  11. Kanazawa H: Anticholinergic agents in asthma: Chronic bronchiodilator therapy, relief of acute severe asthma, reduction of chronic viral inflammation and prevention of remodeling. / Curr Opin Pulm Med 2006,12(1):60鈥?7. CrossRef
  12. Pauwels RA, Buist AS, Calverley PM, / et al.: Global stragegy for diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. / Am J Respir Crit Care Med 2001, 163:1256鈥?6.
  13. Janoff A: Elastases and emphysema: Current assessment of the protease-antiprotease hypothesis. / Am Rev Respir Dis 1985, 132:417鈥?3.
  14. Shapiro SD: Proteinases in chronic obstructive pulmonary disease. / Biochem Soc Trans 2002, 30:98鈥?02. CrossRef
  15. Imai K, Dalal SS, Chen ES, Downey R, Schulman LL, Ginsburg M, D'Armiento J: Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. / Am J Respir Crit Care Med 2001, 163:786鈥?1.
  16. Baraldo S, Bazzan E, Zanin ME, Turato G, Garbisa S, Maestrelli P, Papi A, Miniati M, Fabbri L, Zuin R, Saetta M: Matrix Metalloproteinase-2 protein in lung periphery is related to COPD progression. / CHEST 2007, 132:1733鈥?0. CrossRef
  17. Vernooy JH, Lindeman JH, Jacobs JA, / et al.: Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. / CHEST 2004, 126:1082鈥?0. CrossRef
  18. Russell REK, Russell SV, Culpitt CDM, Donnelly L, Smith M, Wiggins J, Barnes PJ: Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. / Am J Respir Cell Mol Biol 2002, 26:602鈥?9.
  19. Finlay GA, O'Driscoll LR, Russell KJ, D'Arcy EM, Masterson JB, Fitzgerald MX, O'Connor CM: Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. / Am J Respir Crit Care Med 1997, 156:240鈥?47.
  20. Agusti AGN: Systemic effects of chronic obstructive pulmonary disease. / Proc ATS 2005, 2:367鈥?0.
  21. Rodriguez JR, Seals JE, Radin A, / et al.: Neutrophil lysosomal elastase activity in normal subjects and in patients with chronic obstructive lung disease. / Am Rev Respir Dis 1979, 119:409鈥?7.
  22. Waters CM, Sporn PHS, Liu M, Fredberg JJ: EB2002 Symposium Report: Cellular biomechanics in the lung. / Am J Physiol Lung Cell Mol Physiol 2002, 283:L503-L509.
  23. Vlahakis NE, Schroeder MA, Limper AH, Hubmayr RD: Stretch induces cytokine release by alveolar epithelial cells in vitro. / Am J Physiol Lung Cell Mol Physiol 1999, 277:L167-L173.
  24. Ricard JD, Dreyfuss D, Saumon G: Production of inflammatory cytokines in ventilator-induced lung injury: a reappraisal. / Am J Respir Crit Care Med 2001, 163:1176鈥?0.
  25. Bos IST, Gosens R, Zuidhof AB, Schaafsma D, Halayko AJ, Meurs H, Zaagsma J: Inhibition of allergen-induced airway remodelling by tiotropium and budesoneide: a comparison. / Eur Respir J 2007, 30:653鈥?61. CrossRef
  26. Buhling F, Lieder N, Kuhlmann UsC, Waldburg N, Welte T: Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro. / Respir Med 2007, 101:2386鈥?4. CrossRef
  27. Powrie DJ, Wilkinson TMA, Donaldson GC, Jones P, Scrine K, Viel K, KEsten S, edzicha JA: Effect of tiotropium on sputum and serum inflammatory markers and exacrbations in COPD. / Eur Respir J 2007, 30:472鈥?8. CrossRef
  28. Cantor JO: The need for real-time measurement of lung injury in developing an effective treatment for pulmonary emphysema. / Curr Phar Anal 2007, 3:129鈥?32. CrossRef
  29. Anzueto A, Tashkin D, Memjoge S, Kesten S: One year analysis of longitudinal changes in spectrometry in patients with COPD receiving Tiotropium. / Pulm Pharma Ther 2005, 18:75鈥?1. (PMID156鈥?9848) CrossRef
  30. Fregonese L, Fumagalli M, Ferrari F, Luisetti M, Iadarola P, Stolk J: Long-term changes of elastin breakdown priducts in alpha-1 antitrypsin deficiency (Abstract). / Eur Respir J 2007, (supp 51):1408.
  31. Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin R, Papi A, Palladini G, Luisetti M, Annovazzi L, Iadarola P, DeRosa E, Fabbri LM, Mapp C: Markers of emphysema are associated with more severe chronic obstructive pulmonary disease. / Thorax 2006, 61:1037鈥?2. CrossRef
  
• 作者单位：Shuren Ma (1)
  Yong Y Lin (1)
  Lori Tartell (1)
  Gerard M Turino (1)
  
  1. James P. Mara Center for Lung Disease, St. Luke's-Roosevelt Hospital Center, 1000 Tenth Avenue, New York, NY, 10019, USA
  

文摘

Background Desmosine and Isodesmosine (D/I) are cross-linking amino acids which are present only in mature elastin. Changes in their concentration in body fluids indicate changes in elastin degradation and can be a reflection of tissue elastase activity. This study was undertaken to determine whether continuous therapy with the long-acting bronchodilator Tiotropium bromide (TTP) could result in reductions in D/I as measured by mass spectrometry in plasma, urine and sputum. Methods Twelve not currently smoking patients with chronic obstructive pulmonary disease (COPD), never on TTP, were selected for study. Levels of D/I, along with measurements of FVC, FEV1 and FEV1/FVC. were determined before starting TTP daily, and then one and two months after. Results D/I decreased in plasma (10 of 12 patients), in sputum all (12 of 12), and in the percentage of free D/I in urine (10 of 12). Most patients showed slight increases in FVC and FEV1 percent predicted over two months. Conclusion The results are consistent with an effect of prolonged bronchodilitation by anti-cholinergic blockade to also result in reduced lung elastin degradation.